In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Corbus Pharmaceuticals (CRBP), with a price target of $3.00. The company’s shares closed last Monday at $2.27, close to its 52-week low of $0.91.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 20.7% and a 55.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Deciphera Pharmaceuticals.
Corbus Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $2.40.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.78 and a one-year low of $0.91. Currently, Corbus Pharmaceuticals has an average volume of 15.91M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
